Cargando…

A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis

OBJECTIVES: Thrombosis and thrombophlebitis of the superficial venous system are common in hospitalized patients. Efficacy and safety of topical quick penetrating solution (QPS) of heparin were compared to heparin sodium topical gel for the prevention of infusion-associated phlebitis. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Saini, Vikas, Samra, Tanvir, Ahuja, Nitin, Sethi, Sameer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364337/
https://www.ncbi.nlm.nih.gov/pubmed/30783328
http://dx.doi.org/10.4103/ijp.IJP_201_17
_version_ 1783393247287050240
author Saini, Vikas
Samra, Tanvir
Ahuja, Nitin
Sethi, Sameer
author_facet Saini, Vikas
Samra, Tanvir
Ahuja, Nitin
Sethi, Sameer
author_sort Saini, Vikas
collection PubMed
description OBJECTIVES: Thrombosis and thrombophlebitis of the superficial venous system are common in hospitalized patients. Efficacy and safety of topical quick penetrating solution (QPS) of heparin were compared to heparin sodium topical gel for the prevention of infusion-associated phlebitis. MATERIALS AND METHODS: Patients aged 18–65 years undergoing intravenous cannulation for at least 72 h were enrolled and randomized to receive 6–8 drops of topical solution of heparin (Group sodium topical solution [QPS]) or1 g of topical gel (Group GEL) over the cannulated vein every 8 hourly for a total of 10 doses. Enrolled patients were monitored every 8 ± 1 h for phlebitis using visual infusion phlebitis scale. The primary aim was to compare the proportion of patients with Grade 0, I, and II phlebitis at the end of 72 h of treatment period. RESULTS: Number of patients assessed for eligibility was 110; 26 excluded and 84 randomized. Analysis was done for 41 administered heparin QPS and 33 administered heparin gel as the rest were lost to follow-up. No phlebitis was reported in 32% of patients in QPS group and 9% in GEL group (P =0.0019). Proportion of patients with Grade I and Grade II phlebitis was 22.9% and 13.5% with QPS and 35.13% and 22.97% with gel, respectively, and the difference was statistically significant. Mean time to develop Grade I (Group QPS = 59.7 h; Group GEL = 58.46 h; P = 0.949) and Grade II (Group QPS = 62.4 h; Group GEL = 61.17 h; P = 0.732) phlebitis was comparable no adverse effects were reported in either group. CONCLUSION: Heparin QPS was more effective in he prevention of infusion-associated phlebitis with similar safety profile as heparin gel.
format Online
Article
Text
id pubmed-6364337
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63643372019-02-19 A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis Saini, Vikas Samra, Tanvir Ahuja, Nitin Sethi, Sameer Indian J Pharmacol Short Communication OBJECTIVES: Thrombosis and thrombophlebitis of the superficial venous system are common in hospitalized patients. Efficacy and safety of topical quick penetrating solution (QPS) of heparin were compared to heparin sodium topical gel for the prevention of infusion-associated phlebitis. MATERIALS AND METHODS: Patients aged 18–65 years undergoing intravenous cannulation for at least 72 h were enrolled and randomized to receive 6–8 drops of topical solution of heparin (Group sodium topical solution [QPS]) or1 g of topical gel (Group GEL) over the cannulated vein every 8 hourly for a total of 10 doses. Enrolled patients were monitored every 8 ± 1 h for phlebitis using visual infusion phlebitis scale. The primary aim was to compare the proportion of patients with Grade 0, I, and II phlebitis at the end of 72 h of treatment period. RESULTS: Number of patients assessed for eligibility was 110; 26 excluded and 84 randomized. Analysis was done for 41 administered heparin QPS and 33 administered heparin gel as the rest were lost to follow-up. No phlebitis was reported in 32% of patients in QPS group and 9% in GEL group (P =0.0019). Proportion of patients with Grade I and Grade II phlebitis was 22.9% and 13.5% with QPS and 35.13% and 22.97% with gel, respectively, and the difference was statistically significant. Mean time to develop Grade I (Group QPS = 59.7 h; Group GEL = 58.46 h; P = 0.949) and Grade II (Group QPS = 62.4 h; Group GEL = 61.17 h; P = 0.732) phlebitis was comparable no adverse effects were reported in either group. CONCLUSION: Heparin QPS was more effective in he prevention of infusion-associated phlebitis with similar safety profile as heparin gel. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6364337/ /pubmed/30783328 http://dx.doi.org/10.4103/ijp.IJP_201_17 Text en Copyright: © 2019 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Short Communication
Saini, Vikas
Samra, Tanvir
Ahuja, Nitin
Sethi, Sameer
A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
title A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
title_full A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
title_fullStr A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
title_full_unstemmed A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
title_short A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
title_sort prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 iu/ml) compared to heparin topical gel (200 iu/g) in prevention of infusion-associated phlebitis
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364337/
https://www.ncbi.nlm.nih.gov/pubmed/30783328
http://dx.doi.org/10.4103/ijp.IJP_201_17
work_keys_str_mv AT sainivikas aprospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis
AT samratanvir aprospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis
AT ahujanitin aprospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis
AT sethisameer aprospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis
AT sainivikas prospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis
AT samratanvir prospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis
AT ahujanitin prospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis
AT sethisameer prospectiverandomizedstudytoevaluatesafetyandefficacyofheparintopicalsolution1000iumlcomparedtoheparintopicalgel200iuginpreventionofinfusionassociatedphlebitis